The Protective Effect of IDO1 Inhibition in Aβ-Treated Neurons and APP/PS1 Mice

Am J Alzheimers Dis Other Demen. 2023 Jan-Dec:38:15333175231214861. doi: 10.1177/15333175231214861.

Abstract

Alzheimer's disease (AD) is an inflammatory associated disease, in which dysregulated kynurenine pathway (KP) plays a key role. Through KP, L-tryptophan is catabolized into neurotoxic and neuroprotective metabolites. The overactivation of indolamine 2,3-dioxygenase1 (IDO1), the first rate-limiting enzyme of KP, and the abnormal accumulation of KP metabolites have been noted in AD, and blocking IDO1 has been suggested as a therapeutic strategy. However, the expression patterns of KP enzymes in AD, and whether these enzymes are related to AD pathogenesis, have not been fully studied. Herein, we examined the expression patterns of inflammatory cytokines, neurotrophic factors and KP enzymes, and the activity of IDO1 and IDO1 effector pathway AhR (aryl hydrocarbon receptor) in AD mice. We studied the effects of IDO1 inhibitors on Aβ-related neuroinflammation in rat primary neurons, mouse hippocampal neuronal cells, and APP/PS1 mice. The results further demonstrated the importance of IDO1-catalyzed KP in neuroinflammation in Alzheimer's disease.

Keywords: Alzheimer's Disease; Indoleamine 2,3-dioxygenase 1; Indoleamine 2,3-dioxygenase 1 Inhibitor; Kynureninase; Kynurenine Pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Animals
  • Kynurenine / metabolism
  • Mice
  • Neuroinflammatory Diseases
  • Neurons / metabolism
  • Rats
  • Tryptophan / metabolism

Substances

  • Tryptophan
  • Kynurenine